Pruritus, commonly referred to as itching, is a distressing symptom frequently encountered in patients with cholestatic liver diseases. It is particularly prevalent among individuals with primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), intrahepatic cholestasis of pregnancy (ICP), and genetic cholestatic disorders. The symptom can range from mild intermittent discomfort to severe, disabling itching that profoundly affects physical and psychological well-being.

Cholestatic pruritus differs significantly from pruritus associated with dermatological disorders. It often occurs without visible skin lesions, except for secondary excoriations resulting from scratching. The itching predominantly affects the palms, soles, and extremities and is frequently worse during the evening and nighttime. Consequently, sleep disruption and fatigue are common complaints.

The pathogenesis of cholestatic pruritus has challenged researchers for decades. Earlier theories focused primarily on retained bile acids; however, accumulating evidence suggests a multifactorial process involving complex interactions between peripheral and central nervous system pathways. Recent discoveries concerning autotaxin and lysophosphatidic acid have significantly advanced understanding of this condition and provided novel therapeutic targets.

This review aims to provide a comprehensive evidence-based overview of cholestatic pruritus, emphasizing current understanding of pathophysiological mechanisms and evidence-supported management approaches.

Epidemiology

The prevalence of pruritus varies according to the underlying cholestatic disorder. Among patients with PBC, studies report prevalence rates ranging from 40% to 80%. Approximately one-third to one-half of patients with PSC experience clinically significant itching. In ICP, pruritus is the hallmark symptom and occurs in up to 100% of affected women.

Interestingly, symptom severity does not correlate consistently with the degree of liver dysfunction or biochemical cholestasis. Some patients with advanced disease remain asymptomatic, whereas others with relatively mild biochemical abnormalities experience severe itching. This observation supports the notion that factors beyond simple bile acid accumulation contribute to symptom development.

Women appear to be affected more frequently because many cholestatic disorders, particularly PBC and ICP, predominantly occur in females. Younger patients with cholestatic disorders may also report more severe symptoms than older individuals.

Pathophysiology of Cholestatic Pruritus

The pathogenesis of cholestatic pruritus remains incompletely understood. Current evidence suggests that multiple pruritogenic mediators interact with neural pathways responsible for itch perception.

Bile Acids

For many years, retained bile acids were considered the principal cause of cholestatic itching. Elevated serum bile acid concentrations are commonly observed in cholestatic disorders, and interruption of enterohepatic circulation often improves symptoms.

Bile acids may activate itch-sensitive neurons through specific receptors such as Takeda G-protein receptor 5 (TGR5). Experimental studies demonstrate that certain bile acids can stimulate sensory nerve endings and induce scratching behavior in animal models.

However, several observations challenge the theory that bile acids alone are responsible:

• Serum bile acid levels correlate poorly with symptom severity.
• Many patients with elevated bile acids do not experience itching.
• Symptom relief may occur despite persistent biochemical cholestasis.
• Some cholestatic conditions with markedly elevated bile acids are associated with minimal pruritus.

Consequently, bile acids are now regarded as contributors rather than sole mediators.

Autotaxin and Lysophosphatidic Acid

One of the most significant advances in understanding cholestatic pruritus has been the identification of autotaxin and lysophosphatidic acid (LPA).

Autotaxin is a secreted enzyme that converts lysophosphatidylcholine into LPA, a potent neuronal signaling molecule. Elevated serum autotaxin activity has been demonstrated in patients with cholestatic pruritus and correlates strongly with itch intensity.

LPA activates sensory neurons and enhances itch transmission through peripheral and central pathways. Patients with severe cholestatic pruritus consistently exhibit higher autotaxin concentrations than asymptomatic individuals.

The autotaxin-LPA pathway is currently considered one of the most important mechanisms underlying cholestatic itch and represents a promising therapeutic target.

Endogenous Opioid System

Another well-established mechanism involves alterations in endogenous opioid neurotransmission. Cholestasis is associated with increased circulating opioid peptides and enhanced μ-opioid receptor activity.

Activation of μ-opioid receptors promotes itching, whereas κ-opioid receptor stimulation appears to suppress itch signaling. The therapeutic success of opioid antagonists such as naltrexone and naloxone provides strong evidence supporting opioid involvement.

Serotonergic Pathways

Central serotonergic pathways may contribute to itch perception and modulation. Increased serotonergic activity within specific brain regions has been implicated in chronic pruritic conditions.

Clinical trials have shown that sertraline, a selective serotonin reuptake inhibitor, can improve symptoms in patients with refractory cholestatic pruritus, suggesting an important role for serotonin-mediated neural pathways.

Other Potential Mediators

Several additional substances have been investigated:

• Histamine
• Progesterone metabolites
• Substance P
• Endocannabinoids
• Estrogen metabolites
• Protease-activated receptors

Histamine appears to play a limited role, explaining the poor efficacy of antihistamines in cholestatic itch.

Clinical Manifestations

Pruritus associated with cholestasis possesses distinctive clinical characteristics.

Distribution

The itching often begins on:

• Palms
• Soles
• Forearms
• Legs

Over time, it may become generalized.

Temporal Pattern

Common features include:

• Worse during the evening and nighttime
• Aggravation by heat
• Exacerbation during emotional stress
• Fluctuating severity

Associated Symptoms

Patients frequently report:

• Sleep disturbances
• Chronic fatigue
• Irritability
• Anxiety
• Depression
• Reduced work productivity

Physical Examination

Primary skin lesions are absent. Secondary findings may include:

• Excoriations
• Lichenification
• Hyperpigmentation
• Crusted lesions from scratching

Diagnostic Evaluation

The diagnosis of cholestatic pruritus is largely clinical and requires exclusion of alternative causes.

History

Clinicians should assess:

• Duration and severity of symptoms
• Temporal pattern
• Impact on quality of life
• Associated liver-related symptoms
• Medication history
• Family history of liver disease

Laboratory Investigations

Recommended tests include:

• Liver function tests
• Serum bilirubin
• Alkaline phosphatase
• Gamma-glutamyl transferase
• Serum bile acids
• Autoimmune markers
• Viral hepatitis screening

Imaging

Imaging helps identify obstructive and structural causes of cholestasis:

• Ultrasonography
• Magnetic resonance cholangiopancreatography
• Computed tomography
• Endoscopic retrograde cholangiopancreatography when indicated

Assessment Tools

Several validated instruments evaluate symptom severity:

• Visual Analogue Scale (VAS)
• Numerical Rating Scale (NRS)
• 5-D Itch Scale
• PBC-40 quality-of-life questionnaire

Evidence-Based Management

Treatment follows a stepwise approach based on symptom severity and response.

General Measures

Supportive interventions include:

• Regular moisturization
• Avoidance of excessive heat
• Wearing loose clothing
• Maintaining short fingernails
• Psychological support

Although helpful, these measures rarely provide adequate relief alone.

First-Line Therapy: Cholestyramine

Cholestyramine remains the recommended first-line pharmacological treatment.

Mechanism

It binds bile acids in the intestinal lumen and interrupts enterohepatic circulation.

Evidence

Multiple studies and international guidelines support its use. Symptom improvement occurs in a substantial proportion of patients.

Limitations

Common adverse effects include:

• Constipation
• Bloating
• Nausea
• Poor palatability

Drug interactions necessitate administration several hours apart from other medications.

Second-Line Therapy: Rifampicin

Rifampicin is considered the most effective second-line agent.

Mechanism

It activates the pregnane X receptor and promotes detoxification of potential pruritogens.

Evidence

Numerous randomized controlled trials demonstrate significant symptom reduction.

Safety Considerations

Monitoring is required for:

• Hepatotoxicity
• Hemolytic anemia
• Renal impairment
• Drug interactions

Third-Line Therapy: Opioid Antagonists

Naltrexone

Naltrexone effectively reduces itching by blocking μ-opioid receptors.

Evidence

Several controlled trials report substantial improvement in patients with refractory disease.

Adverse Effects

Potential side effects include:

• Abdominal pain
• Nausea
• Dizziness
• Opioid withdrawal-like symptoms

Careful dose escalation is recommended.

Fourth-Line Therapy: Sertraline

Sertraline is increasingly used in refractory cases.

Mechanism

The drug modulates central serotonergic neurotransmission.

Evidence

Randomized studies demonstrate meaningful symptom improvement and enhanced quality of life.

Emerging Therapeutic Approaches

Ileal Bile Acid Transporter Inhibitors

IBAT inhibitors reduce intestinal bile acid reabsorption and decrease circulating pruritogens.

Clinical trials have demonstrated significant reductions in itching severity, particularly in genetic cholestatic disorders.

Fibrates

Bezafibrate and fenofibrate may improve cholestasis and reduce pruritus through activation of peroxisome proliferator-activated receptors.

κ-Opioid Receptor Agonists

Selective κ-opioid receptor agonists represent a promising therapeutic strategy by suppressing itch signaling pathways.

Autotaxin Inhibitors

Novel therapies directly targeting autotaxin are under investigation and may offer highly specific treatment options in the future.

Extracorporeal and Interventional Therapies

Patients with severe refractory symptoms may require advanced interventions.

Plasmapheresis

Plasmapheresis temporarily removes circulating pruritogens and can provide short-term relief.

Molecular Adsorbent Recirculating System (MARS)

MARS therapy removes protein-bound toxins and has shown efficacy in severe cholestatic pruritus.

Nasobiliary Drainage

Selected patients with obstructive cholestatic disorders may benefit from nasobiliary drainage.

Liver Transplantation

For patients with intractable symptoms unresponsive to medical therapy, liver transplantation remains the definitive treatment.

Importantly, severe refractory pruritus alone may justify transplantation despite preserved hepatic synthetic function.

Most patients experience dramatic and sustained symptom resolution following transplantation, leading to substantial improvements in quality of life.

Study Design This study was conducted as an evidence-based systematic and narrative review to evaluate the current understanding of the pathophysiology, clinical manifestations, diagnostic evaluation, and management of pruritus in cholestatic liver diseases. The review methodology was developed in accordance with the Preferred Reporting Items for Systematic Reviews. Search Strategy A comprehensive literature search was performed using the electronic databases PubMed/MEDLINE, Scopus, Embase, Web of Science, and the Cochrane Library. The search included studies published from January 2000 to March 2026. Additional relevant articles were identified through manual screening of reference lists from eligible studies and major clinical guidelines. The following keywords and Medical Subject Headings (MeSH) terms were used in various combinations: "pruritus," "cholestatic pruritus," "cholestasis," "cholestatic liver disease," "primary biliary cholangitis," "primary sclerosing cholangitis," "intrahepatic cholestasis of pregnancy," "bile acids," "autotaxin," "lysophosphatidic acid," "itch," "management," "treatment," "rifampicin," "cholestyramine," "naltrexone," "sertraline," "IBAT inhibitors," and "liver transplantation." Eligibility Criteria Inclusion Criteria  Original research articles, randomized controlled trials, cohort studies, case-control studies, systematic reviews, meta-analyses, and clinical practice guidelines.  Studies involving adult or pediatric patients with cholestatic liver diseases.  Studies evaluating pathophysiological mechanisms, clinical characteristics, diagnostic approaches, or therapeutic interventions for cholestatic pruritus.  Articles published in English. Exclusion Criteria  Case reports with fewer than five patients.  Conference abstracts lacking full-text availability.  Animal studies without clinical relevance.  Non-English publications.  Studies addressing pruritus unrelated to cholestatic liver disease. Study Selection Titles and abstracts retrieved through database searches were independently screened for relevance. Full-text articles were subsequently assessed for eligibility according to predefined inclusion and exclusion criteria. Duplicate records were removed before screening. Any discrepancies regarding study eligibility were resolved through discussion and consensus. Data Extraction Data extracted from eligible studies included:  Author and year of publication  Study design  Sample size  Underlying cholestatic disorder  Pathophysiological findings  Therapeutic interventions  Clinical outcomes  Adverse events  Key conclusions

and distressing manifestations of cholestatic liver disease. Although considerable progress has been made in understanding its pathogenesis, the precise mechanisms responsible for itch generation and persistence are not yet fully elucidated. The findings of this review support the current concept that cholestatic pruritus is a multifactorial phenomenon involving complex interactions between peripheral pruritogens, neural signaling pathways, and central nervous system modulation.

Historically, bile acids were considered the principal mediators of cholestatic itch. While experimental and clinical evidence suggests that bile acids contribute to symptom development, their inconsistent correlation with itch severity indicates that additional mechanisms are involved. The identification of the autotaxin–lysophosphatidic acid (LPA) pathway has significantly advanced the field and provides one of the strongest mechanistic explanations for cholestatic pruritus. Elevated autotaxin activity has consistently been associated with increased itch severity, highlighting its potential role as both a biomarker and therapeutic target.

The endogenous opioid system also appears to play an important role in symptom generation. Increased μ-opioid receptor activity and altered opioid neurotransmission observed in cholestatic states may explain the beneficial effects of opioid antagonists such as naltrexone. Similarly, evidence supporting serotonergic involvement is reinforced by clinical studies demonstrating symptom improvement with sertraline. These observations suggest that both peripheral and central neural mechanisms contribute to the perception and modulation of itch in cholestatic disorders.

From a therapeutic perspective, current management remains largely empirical and follows a stepwise approach. Cholestyramine continues to be recommended as first-line therapy because of its safety profile and longstanding clinical experience. Rifampicin has demonstrated consistent efficacy in randomized controlled trials and remains the preferred second-line agent despite concerns regarding hepatotoxicity and drug interactions. Opioid antagonists and selective serotonin reuptake inhibitors provide valuable alternatives for patients who fail conventional therapies.

One of the most significant developments in recent years has been the emergence of ileal bile acid transporter (IBAT) inhibitors. Agents such as maralixibat and odevixibat have shown encouraging results in reducing pruritus severity, particularly in genetic cholestatic disorders. These therapies target disease-specific pathways and represent an important shift toward mechanism-based treatment strategies. Furthermore, ongoing investigations of autotaxin inhibitors and κ-opioid receptor agonists may further expand the therapeutic landscape.

Despite these advances, several challenges remain. Many available studies involve relatively small patient populations, and direct comparisons between therapeutic agents are limited. Additionally, the subjective nature of itch assessment and variability among outcome measures complicate interpretation of treatment efficacy. Standardization of pruritus assessment tools and incorporation of patient-reported outcome measures are essential for future research.

The findings of this review emphasize the need for continued investigation into the biological mechanisms underlying cholestatic pruritus. Improved understanding of molecular pathways may facilitate the development of personalized treatment approaches and novel targeted therapies. Future large-scale randomized controlled trials are required to establish optimal treatment algorithms and evaluate the long-term safety and efficacy of emerging therapeutic agents.

Overall, contemporary evidence supports a multifaceted pathophysiological model of cholestatic pruritus and underscores the importance of a structured, evidence-based approach to management. Advances in translational research continue to improve understanding of this debilitating condition and offer hope for more effective therapeutic interventions in the future.

Future Directions

Future research should focus on:

• Better identification of pruritogenic mediators
• Development of autotaxin-targeted therapies
• Biomarker-guided treatment strategies
• Precision medicine approaches
• Long-term evaluation of IBAT inhibitors
• Novel neuroimmune therapeutic targets

These advances may transform management and improve outcomes for patients suffering from cholestatic itch.

Cholestatic pruritus is a complex and often debilitating manifestation of cholestatic liver disease. Contemporary evidence supports a multifactorial pathogenesis involving bile acids, endogenous opioids, serotonergic pathways, and particularly the autotaxin-LPA signaling axis. Effective management requires a structured approach beginning with cholestyramine and progressing through rifampicin, opioid antagonists, and sertraline. Emerging therapies, especially IBAT inhibitors and targeted molecular interventions, offer promising alternatives for refractory disease. Continued research into the biological mechanisms of cholestatic itch is expected to yield more effective and personalized treatment strategies.